Carbenicillin
| Clinical data | |
|---|---|
| Trade names | Geocillin; Pyopen |
| Other names | CB |
| AHFS/Drugs.com | Monograph |
| Pregnancy category |
|
| Routes of administration | Oral, parenteral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 30 to 40% |
| Protein binding | 30 to 60% |
| Metabolism | Minimal |
| Elimination half-life | 1 hour |
| Excretion | Renal (30 to 40%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.022.882 |
| Chemical and physical data | |
| Formula | C17H18N2O6S |
| Molar mass | 378.40 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (what is this?) (verify) | |
Carbenicillin is a bactericidal antibiotic belonging to the carboxypenicillin subgroup of the penicillins. It was discovered by scientists at Beecham and marketed as Pyopen. It has Gram-negative coverage which includes Pseudomonas aeruginosa but limited Gram-positive coverage. The carboxypenicillins are susceptible to degradation by beta-lactamase enzymes, although they are more resistant than ampicillin to degradation. Carbenicillin is also more stable at lower pH than ampicillin.